About NovaGo
Founded in 2015 in Schlieren, Switzerland, NovaGo Therapeutics is a development stage biotech company focused on human antibody therapeutics targeting nerve growth and regeneration for the treatment of spinal cord injury. NovaGo’s therapeutic antibody candidates enhance nerve repair and functional recovery in preclinical models. Phase 1 clinical trials are expected to start in 2024.
The management team has a proven track record in research and drug development. NovaGo collaborates with Neurimmune (www.neurimmune.com) on the research and development of human therapeutic antibodies to block Nogo-A function. In March 2019 NovaGo successfully closed a Series A financing round of CHF 10 million (USD11 million) led by Pureos Bioventures and Neurimmune.